Clinical cohort characteristics
| n | Female sex n (%) | Mean age in years (range) | Mean disease duration since manifestation in years±SD (range) | Mean treatment duration in months±SD (range) | |
| Untreated | 21 | 12 (57) | 51 (28–68) | 20±8 (3–36) | NA |
| aCD20-BCD | 36 | 23 (64) | 42 (28–58) | 15±9 (1–33) | 26±12 (2–51) |
| Fingolimod | 31 | 24 (77) | 45 (21–68) | 16±6 (7–33) | 87±50 (9–167) |
| IFNβ | 7 | 7 (100) | 42 (34–58) | 11±6 (3–20) | 102±44 (20–180) |
| DMF | 10 | 8 (80) | 45 (33–55) | 15±9 (1–29) | 90±28 (12–155) |
| GA | 8 | 6 (75) | 47 (34–61) | 13±8 (1–26) | 99±32 (15–144) |
| TFN | 9 | 7 (78) | 46 (31–55) | 11±7 (1–20) | 81±50 (14–188) |
| NTZ | 4 | 2 (50) | 45 (31–56) | 13±12 (2–26) | 55±21 (13–70) |
DMF, dimethyl fumarate; GA, glatiramer acetate; IFNβ, Interferon-β; n, number; NA, not applicable; NTZ, natalizumab; TFN, teriflunomide.